Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing

Ying-Ying Cheng1,2,3, Bei-Yu Chen2, Gan-Lan Bian4,5

  • 1Department of Anatomy, Histology and Embryology, The Key Laboratory of Cerebrocranial Diseases, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.

Molecular Neurobiology
|February 10, 2022
PubMed

Insights

Programmed death-1 (PD-1) deficiency worsens motor deficits in Parkinson's disease (PD) models by increasing neuroinflammation and microglial activation. This suggests PD-1 signaling plays a protective role in PD pathogenesis.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Parkinson's disease (PD) is characterized by reactive gliosis and neuroinflammation, but underlying regulatory mechanisms remain unclear.
  • The role of programmed death-1 (PD-1) in glial responses, neuroinflammation, and neuronal injury in PD pathogenesis requires investigation.

Purpose of the Study:

  • To investigate the role of programmed death-1 (PD-1) in glial activation, neuroinflammation, and neuronal injury within a Parkinson's disease (PD) mouse model.

Main Methods:

  • Utilized a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mouse model and PD-1 knockout (KO) mice.
  • Assessed motor dysfunction via behavior detection.
  • Analyzed dopaminergic neuronal injury, glial activation, and inflammatory cytokine generation using immunohistochemistry and western blot.

Main Results:

  • PD-1 deficiency exacerbated motor dysfunction and dopaminergic neuronal loss in the MPTP model.
  • PD-1 deficiency led to increased microglial activation and elevated levels of pro-inflammatory cytokines (iNOS, TNF-α, IL-1β, IL-6).
  • Enhanced phosphorylation of AKT and ERK1/2 was observed in the substantia nigra of PD-1 deficient mice.

Conclusions:

  • PD-1 deficiency aggravates motor dysfunction in the MPTP mouse model by promoting microglial activation and neuroinflammation.
  • These findings suggest that PD-1 signaling abnormalities may contribute to Parkinson's disease pathogenesis.